NCT03401047View on ClinicalTrials.gov

Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 30, 2017

Primary Completion Date

October 1, 2025

Study Completion Date

December 1, 2025

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

Estradiol

Subjects will receive graded doses of transdermal estradiol patches for up to 7 days. Blood estradiol tests will be performed daily, and the number of estradiol patches used will be adjusted to maintain serum estradiol levels of 250-400 pg/ml. Estradiol is a natural hormone.

Trial Locations (1)

22908

RECRUITING

University of Virginia Clinical Research Unit, Charlottesville

All Listed Sponsors
lead

University of Virginia

OTHER